// App-Quantinova.ai

: Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Researchers

Presenter

  • Philip C. Amrein

Principal Investigators

  • Traci M. Blonquist

  • Andrew M. Brunner

  • Gabriela S. Hobbs

  • Hanno Hock

  • Steven L McAfee

  • Jenna A. Moran

  • Meghan Bergeron

  • Julia Foster

  • Christina Bertoli

  • Kristin McGregor

  • Molly Macrae

  • Meghan Burke

  • Tanya T. Behnan

  • Tina T. Som

  • Aura Y. Ramos

  • Megan K. Vartanian

  • Jennifer Lombardi Story

  • Christine Connolly

  • Donna S Neuberg

  • Amir T. Fathi

Medical Centers

  • Transplant Center, Massachusetts General Hospital, Boston, MA

  • Massachusetts General Hospital, Boston, MA

  • Hematology Oncology, University of Virginia, Charlottesville, VA

  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Ph chromosome

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • PEG-asparaginase

  • Hydrocortisone

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Asparaginase

  • Vincristine

  • Doxorubicin

  • Cytarabine liposomal

  • Prednisone

  • Ixazomib

  • L-Tyrosine

  • Filgrastim

  • 6-mercaptopurine

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved